



## ViziLite Oral Screening Consent Form

### **One American dies every hour from oral cancer.**

As with most cancers, **AGE** is the **primary** risk factor. **27% of oral cancer victims do not smoke or drink.**

#### At highest risk:

- individuals ages 40 and older with lifestyle risk factors that include:
  - tobacco use (any type within 10 years)
  - alcohol consumption of one+ drinks per day
  - previous history of oral cancer
  - autoimmune deficiencies such as HIV and AIDS
  - viral infections, particularly human papilloma virus
  - diabetes

#### At high risk:

- individuals ages 40 and older with no lifestyle risk factors
- individuals younger than 40 with lifestyle risk factors

#### At increased risk:

- individuals ages 18 to 39

The American Cancer Society indicates that more women in the United States will be diagnosed with oral cancer this year (>12,000 cases) than cervical cancer (<10,000 cases). Furthermore, there are now as many cases of oral cancer caused by the sexually transmitted disease of human papilloma virus (HPV) as HPV-related cases of cervical cancer. The death rate in the United States for oral cancer is higher than that of cervical cancer, Hodgkin's disease, and cancer of the brain, liver, testes, kidney, or ovary, **but oral cancer is 90% curable when found in early stages.**

ViziLite Plus is an early detection procedure like the mammogram, Pap smear, Prostate Specific Antigen test, and colonoscopy. We recommend it for guests ages 18 and over once per year. ViziLite Plus allows us to identify suspicious areas of the mouth at the earliest possible stages during the oral cancer screenings we perform at every periodic exam. Early detection of pre-cancerous tissue can minimize or eliminate the potentially disfiguring effects of oral cancer. Early detection can save your life.

[www.meetinghousedental.com](http://www.meetinghousedental.com)

Meetinghouse Dental Care is committed to the art of dentistry through leading-edge technology and personalized, comfortable care.

Louis L. Trovato,  
DDS, FAGD, FAACP, FICOI  
Wendy M. Beratan, DMD  
865 West County Line Road  
Hatboro, PA 19040  
Phone: 215.293.0909  
Fax: 215.293.0901

100% Guaranteed  
Family Dentistry  
Since 1983

Cosmetic Dentistry

Craniomandibular  
And TMJ Dysfunction  
Therapy

Full Mouth  
Rehabilitative and  
Reconstructive  
Dentistry

Implant Dentistry

Functional Jaw  
Orthopedics

Adult Orthodontics

#### *Professional Memberships:*

Academy of  
General Dentistry

American Academy  
Of Cosmetic  
Dentistry

American Academy  
Of Craniofacial Pain

Pennsylvania  
Craniomandibular  
Society

International Association  
For Functional  
Orthodontics

International Congress  
Of Oral Implantology

American College of  
Oral Implantology

American College  
Of Prosthetic Dentistry

American Dental  
Association

Montgomery Bucks  
Dental Society

Your investment for this procedure is \$60.

*Read if you have dental insurance:*

The American Dental Association has recognized ViziLite Plus with the CDT-5 code of D0431. Even so, not all dental insurance contracts currently support the procedure. If you have dental insurance, we will submit your claim but request you pay at the time of service until your particular reimbursement status can be determined. If your contract reimburses the claim, we will credit your account accordingly and note eligibility for future claims.

*Read if you have non-HMO medical insurance:*

We will provide you with a coded medical claim form if you wish to submit the ViziLite Plus procedure to your medical insurance. (You may not submit the claim both to dental and to medical.)

YES. I authorize my dental providers to perform the ViziLite Plus exam during their standard oral cancer examination. I accept financial responsibility for this procedure.

Guest Name: \_\_\_\_\_

Guest Signature: \_\_\_\_\_ Date: \_\_\_\_\_

NO. I do not choose to have the ViziLite Plus exam at this time.

Guest Name: \_\_\_\_\_

Guest Signature: \_\_\_\_\_ Date: \_\_\_\_\_

NOTE: The safety and clinical efficacy of the ViziLite chemiluminescence screening technology in identifying early signs of oral cancer has been demonstrated in over 13,000 patients and four FDA studies. Abstracts, clinical data, and more information are available at [www.vizilite.com](http://www.vizilite.com).